Best Oesophageal Cancer Treatment Doctors in India

What Patients with Oesophageal Cancer Worry About Most

Oesophageal cancer often presents late with progressive difficulty swallowing, weight loss, and reflux. Patients tell us the diagnosis arrived after months of being treated for reflux disease. Families ask: can the cancer be removed, will I be able to eat normally afterwards, do I need chemotherapy and radiation, and what is my survival. The fear of complex surgery and prolonged recovery is real because oesophagectomy is one of the bigger operations in cancer surgery. Modern Indian centres use minimally invasive thoracoscopic and robotic approaches that reduce complications and recovery time significantly.

How Oesophageal Cancer Is Diagnosed

Diagnosis requires upper endoscopy with biopsy. The two main histologies are squamous cell carcinoma (more common in the upper and middle oesophagus, often associated with smoking and alcohol) and adenocarcinoma (more common in the lower oesophagus, often associated with reflux disease and Barrett’s oesophagus). Staging uses endoscopic ultrasound for local T and N staging, computed tomography of the chest and abdomen, and positron emission tomography combined with computed tomography for distant disease. Bronchoscopy is done if airway involvement is suspected. HER2 testing is done in adenocarcinoma, and programmed death-ligand 1 testing in selected cases.

Treatment Options for Oesophageal Cancer in India

Early-stage disease may be treated with endoscopic resection (endoscopic submucosal dissection) for very early tumours. Locally advanced disease is treated with neoadjuvant chemoradiation followed by surgery (the CROSS regimen), or with perioperative chemotherapy. Oesophagectomy is the curative surgery, with minimally invasive thoracoscopic and robotic approaches now standard at major centres. The Ivor Lewis and McKeown approaches are both used depending on tumour location. For metastatic disease, chemotherapy with FLOT, FOLFOX, or platinum plus 5-fluorouracil regimens is used. Trastuzumab is added for HER2-positive adenocarcinoma. Immunotherapy (pembrolizumab, nivolumab) is now standard for advanced disease and is being used in earlier settings. Centres at Tata Memorial, Apollo, Medanta, Fortis Memorial Research Institute, and Max have high-volume oesophageal cancer programmes.

Recovery, Success Rates, and Follow-Up

Outcomes have improved with multimodality treatment. Early-stage disease has five-year survival above sixty percent. Locally advanced disease treated with neoadjuvant chemoradiation and surgery sits around thirty to forty percent. Metastatic disease has shorter survival but immunotherapy is improving outcomes. Hospital stay after minimally invasive oesophagectomy is around eight to twelve days. Patients usually start on liquid diet, progressing to soft and then normal food over weeks. Some patients have ongoing reflux, dumping syndrome, or anastomotic strictures needing endoscopic dilatation. Follow-up runs for at least five years with imaging, endoscopy, and nutritional review.

How to Choose the Right Doctor

Oesophagectomy is a complex operation where high-volume surgeons have better outcomes. Look for a thoracic or upper gastrointestinal surgical oncologist with at least ten years of focused experience and the centre doing at least twenty oesophagectomies a year. Questions to ask: the surgeon’s annual volume, whether minimally invasive or robotic oesophagectomy is offered, the centre’s anastomotic leak rate, the involvement of medical and radiation oncology in neoadjuvant treatment, and the post-operative critical care and nutrition support. Centres at Tata Memorial, Apollo, Medanta, Fortis Memorial Research Institute, and Max have established oesophageal cancer programmes.

Support for International Patients

Treatment in India is significantly more affordable than equivalent care in the United Kingdom, United States, Middle East, or Southeast Asia. Final pricing depends on the stage, type of surgery, chemoradiation, and whether targeted therapy or immunotherapy is needed. Cancer Rounds arranges the medical visa invitation letter, accommodation, multilingual support in eleven plus languages, and full coordination through pre-operative chemoradiation, surgery, hospital stay, and follow-up. Patients from Nigeria, Bangladesh, Oman, Kuwait, Qatar, Kenya, Uganda, Tanzania, Ghana, Ethiopia, Cameroon, Mauritius, Mozambique, Senegal, Zimbabwe, Zambia, Guinea, Liberia, Madagascar, South Sudan, Qatar, Chad, Sierra Leone, Congo, Iraq & Uzbekistan, and other countries travel to India for oesophageal cancer treatment.

Frequently Asked Questions

Can oesophageal cancer be cured?

Yes, particularly in early and locally advanced stages. Early-stage disease has five-year survival above sixty percent. Locally advanced disease treated with multimodality therapy sits around thirty to forty percent.

Will I be able to eat normally after surgery?

Most patients return to a near-normal diet over weeks to months. Smaller, more frequent meals work better. Some patients have ongoing reflux, dumping syndrome, or strictures that need endoscopic dilatation, all manageable.

Do I need chemotherapy and radiation before surgery?

Locally advanced oesophageal cancer is now standardly treated with neoadjuvant chemoradiation (the CROSS regimen) followed by surgery, or with perioperative chemotherapy (the FLOT regimen). This approach improves cure rates significantly.

What is minimally invasive oesophagectomy?

Minimally invasive oesophagectomy uses thoracoscopic and laparoscopic or robotic techniques to remove the oesophagus through small incisions instead of large open ones. Outcomes are equivalent or better with faster recovery and fewer complications.

Is immunotherapy used for oesophageal cancer?

Yes. Immunotherapy (pembrolizumab, nivolumab) is now standard for advanced or metastatic disease and is being used after surgery in selected cases to reduce recurrence risk.

What if surgery is not possible?

Patients not fit for surgery or with metastatic disease are treated with definitive chemoradiation, palliative chemotherapy with immunotherapy, oesophageal stenting to relieve swallowing problems, and supportive care. Cure is less likely but the disease can be controlled.